EGFR and lung adenocarcinoma: As several randomized trials have extensively demonstrated, the presence of a classic sensitizing EGFR mutation is the most powerful predictive biomarker of response to monotherapy with first-generation TKIs and, thus, the most important prognostic factor in cases of advanced lung adenocarcinoma [25,33,34,35].